<code id='ECB2C8D14B'></code><style id='ECB2C8D14B'></style>
    • <acronym id='ECB2C8D14B'></acronym>
      <center id='ECB2C8D14B'><center id='ECB2C8D14B'><tfoot id='ECB2C8D14B'></tfoot></center><abbr id='ECB2C8D14B'><dir id='ECB2C8D14B'><tfoot id='ECB2C8D14B'></tfoot><noframes id='ECB2C8D14B'>

    • <optgroup id='ECB2C8D14B'><strike id='ECB2C8D14B'><sup id='ECB2C8D14B'></sup></strike><code id='ECB2C8D14B'></code></optgroup>
        1. <b id='ECB2C8D14B'><label id='ECB2C8D14B'><select id='ECB2C8D14B'><dt id='ECB2C8D14B'><span id='ECB2C8D14B'></span></dt></select></label></b><u id='ECB2C8D14B'></u>
          <i id='ECB2C8D14B'><strike id='ECB2C8D14B'><tt id='ECB2C8D14B'><pre id='ECB2C8D14B'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:knowledge    Page View:5142
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In